Hungarian Multicenter Non-Interventional Study of Continued Avastin (Bevacizumab) Plus Chemotherapy Until First Progression Following Induction Treatment With Chemotherapy Doublet Plus Avastin in First Line Treatment of Patients With Metastatic Colorectal Carcinoma
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms AVACONT
- Sponsors Roche
- 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Sep 2016 Planned End Date changed from 1 Mar 2018 to 1 Dec 2017.
- 01 Sep 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2017.